Skip to main content

Compare Stocks

Date Range: 

 Anchiano TherapeuticsCerecorMereo BioPharma GroupCitius PharmaceuticalsMediciNova
SymbolNASDAQ:ANCNNASDAQ:CERCNASDAQ:MREONASDAQ:CTXRNASDAQ:MNOV
Price Information
Current Price$16.59$2.20$3.10$1.96$4.16
52 Week RangeN/ABuyBuyBuyBuy
MarketRank™
Overall Score0.81.81.51.31.2
Analysis Score0.03.53.53.53.5
Community Score2.52.92.42.32.7
Dividend Score0.00.00.00.00.0
Ownership Score1.72.50.80.00.0
Earnings & Valuation Score0.00.00.60.60.0
Analyst Ratings
Consensus RecommendationN/ABuyBuyBuyBuy
Consensus Price TargetN/A$7.50$10.00$5.00$13.00
% Upside from Price TargetN/A240.91% upside222.58% upside155.10% upside212.50% upside
Trade Information
Market Cap$123.10 million$210.01 million$210.15 million$246.54 million$202.88 million
Beta0.931.671.691.481.4
Average Volume3,145,6481,686,2022,089,89611,530,723716,153
Sales & Book Value
Annual RevenueN/A$6.75 millionN/AN/AN/A
Price / SalesN/A31.11N/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.01 per share$0.40 per share$2.06 per share$0.61 per share$1.71 per share
Price / BookN/A5.50N/AN/AN/A
Profitability
Net Income$-27,120,000.00$-16,070,000.00$-44,490,000.00$-17,550,000.00$-12,940,000.00
EPS($3.46)($0.30)($2.49)N/AN/A
Trailing P/E Ratio110.60N/AN/A0.000.00
Forward P/E RatioN/AN/AN/A4.00N/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-799.40%N/AN/AN/A
Return on Equity (ROE)36.08%-93.78%N/A-62.67%-17.56%
Return on Assets (ROA)27.40%-61.01%N/A-48.27%-16.62%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.60%N/AN/A
Current Ratio3.25%2.48%2.99%3.41%34.68%
Quick Ratio3.25%2.48%N/A3.41%34.68%
Ownership Information
Institutional Ownership Percentage9.05%66.41%62.14%1.89%21.65%
Insider Ownership Percentage6.88%58.00%N/A33.90%16.00%
Miscellaneous
Employees163038109
Shares Outstanding7.42 million95.46 million67.79 million125.79 million48.77 million
Next Earnings DateN/A8/5/2021 (Estimated)6/30/2021 (Estimated)8/13/2021 (Estimated)7/27/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
MediciNova: Q1 Earnings Snapshot - Raleigh News & ObserverMediciNova: Q1 Earnings Snapshot - Raleigh News & Observer
newsobserver.com - May 14 at 6:20 PM
MediciNova: Q1 Earnings Snapshot - Sacramento BeeMediciNova: Q1 Earnings Snapshot - Sacramento Bee
sacbee.com - May 14 at 1:19 PM
MediciNova: Q1 Earnings Snapshot - SFGateMediciNova: Q1 Earnings Snapshot - SFGate
sfgate.com - May 14 at 8:19 AM
MediciNova Reports First Quarter 2021 Financial Results and - GlobeNewswireMediciNova Reports First Quarter 2021 Financial Results and - GlobeNewswire
globenewswire.com - May 14 at 8:19 AM
MediciNova Reports First Quarter 2021 Financial Results and Business UpdateMediciNova Reports First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 14 at 8:19 AM
MediciNova Secures European Patent for MN-166 Plus Riluzole - ALS News TodayMediciNova Secures European Patent for MN-166 Plus Riluzole - ALS News Today
alsnewstoday.com - May 13 at 10:57 AM
MNOV Stock: 4.71% Increase (From $4.25 To $4.45) Pre-Market Explanation - Pulse 2.0MNOV Stock: 4.71% Increase (From $4.25 To $4.45) Pre-Market Explanation - Pulse 2.0
pulse2.com - May 6 at 2:37 PM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 - GlobeNewswireMediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 - GlobeNewswire
globenewswire.com - May 5 at 9:06 PM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in EuropeMediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe
finance.yahoo.com - May 5 at 9:06 PM
Zacks: Brokerages Anticipate MediciNova, Inc. (NASDAQ:MNOV) Will Post Earnings of -$0.08 Per ShareZacks: Brokerages Anticipate MediciNova, Inc. (NASDAQ:MNOV) Will Post Earnings of -$0.08 Per Share
americanbankingnews.com - April 29 at 2:35 PM
Alcohol Addiction Pipeline Analysis: Key Pharma Companies Set to Develop Innovative Therapies and Explore Countless Opportunities - GlobeNewswireAlcohol Addiction Pipeline Analysis: Key Pharma Companies Set to Develop Innovative Therapies and Explore Countless Opportunities - GlobeNewswire
globenewswire.com - April 28 at 12:17 AM
The MediciNova Riddle: Worth Unravelling - Seeking AlphaThe MediciNova Riddle: Worth Unravelling - Seeking Alpha
seekingalpha.com - April 26 at 7:03 PM
MNOV: Milestone Payments from Legacy Gene Therapy Assets... - Yahoo FinanceMNOV: Milestone Payments from Legacy Gene Therapy Assets... - Yahoo Finance
finance.yahoo.com - April 26 at 2:03 PM
MNOV: Milestone Payments from Legacy Gene Therapy Assets...MNOV: Milestone Payments from Legacy Gene Therapy Assets...
finance.yahoo.com - April 26 at 2:03 PM
MediciNova (MNOV) Shares Rise; Receives $4 Million in Milestone Payments - InvestorsObserverMediciNova (MNOV) Shares Rise; Receives $4 Million in Milestone Payments - InvestorsObserver
investorsobserver.com - April 22 at 5:53 PM
MediciNova Receives Gene Therapy Milestone Payments Nasdaq:MNOV - GlobeNewswireMediciNova Receives Gene Therapy Milestone Payments Nasdaq:MNOV - GlobeNewswire
globenewswire.com - April 22 at 7:52 AM
MediciNova Receives Gene Therapy Milestone PaymentsMediciNova Receives Gene Therapy Milestone Payments
finance.yahoo.com - April 22 at 7:52 AM
Global Spasticity Treatment Market Growth And Outlook By 2026 | Sanofi, MediciNova, Taj Pharmaceuticals, InMed Pharmaceuticals, Ipsen - Clark County BlogGlobal Spasticity Treatment Market Growth And Outlook By 2026 | Sanofi, MediciNova, Taj Pharmaceuticals, InMed Pharmaceuticals, Ipsen - Clark County Blog
clarkcountyblog.com - April 20 at 6:23 PM
Idiopathic Pulmonary Fibrosis Market to Witness Strong Growth Over 2021-2027 | Key Manufacturers Overview- MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, etc. – Clark County Blog - Clark County BlogIdiopathic Pulmonary Fibrosis Market to Witness Strong Growth Over 2021-2027 | Key Manufacturers Overview- MediciNova, Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Promedior, etc. – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 19 at 7:51 PM
MediciNova to Participate in the B. Riley Neuroscience Conference - Northeast Mississippi Daily JournalMediciNova to Participate in the B. Riley Neuroscience Conference - Northeast Mississippi Daily Journal
djournal.com - April 19 at 2:50 PM
MediciNova to Participate in the B. Riley Neuroscience Conference - GlobeNewswireMediciNova to Participate in the B. Riley Neuroscience Conference - GlobeNewswire
globenewswire.com - April 19 at 9:48 AM
MediciNova to Participate in the B. Riley Neuroscience ConferenceMediciNova to Participate in the B. Riley Neuroscience Conference
finance.yahoo.com - April 19 at 9:47 AM
Think You Need A Good Stock? Look At This MediciNova, Inc. (NASDAQ:MNOV) AnalysisThink You Need A Good Stock? Look At This MediciNova, Inc. (NASDAQ:MNOV) Analysis
stocksregister.com - April 18 at 3:36 AM
How much of Asias Shares Account for Pulmonary Fibrosis Market? - Los Hijos de la MalincheHow much of Asia's Shares Account for Pulmonary Fibrosis Market? - Los Hijos de la Malinche
loshijosdelamalinche.com - April 17 at 7:13 AM
Global Idiopathic Pulmonary Fibrosis Market Report 2021-2025 By Top Trending Manufacturers, Merck & Co., MediciNova, Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., FibroGen, Inc. - Los Hijos de la MalincheGlobal Idiopathic Pulmonary Fibrosis Market Report 2021-2025 By Top Trending Manufacturers, Merck & Co., MediciNova, Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., FibroGen, Inc. - Los Hijos de la Malinche
loshijosdelamalinche.com - April 15 at 3:00 PM
DateCompanyBrokerageAction
11/18/2019Anchiano TherapeuticsRobert W. BairdDowngrade
11/18/2019Anchiano TherapeuticsOppenheimerDowngrade
11/18/2019Anchiano TherapeuticsLADENBURG THALM/SH SHDowngrade
4/27/2021CerecorMaxim GroupUpgrade
4/26/2021CerecorJefferies Financial GroupInitiated Coverage
4/15/2020CerecorHC WainwrightReiterated Rating
5/11/2021Mereo BioPharma GroupBTIG ResearchInitiated Coverage
4/5/2021Mereo BioPharma GroupNeedham & Company LLCInitiated Coverage
10/10/2019Mereo BioPharma GroupSVB LeerinkReiterated Rating
2/25/2021Citius PharmaceuticalsDawson JamesReiterated Rating
8/3/2020MediciNovaB. RileyReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.